
ICVX
Healthcare · Biotechnology · $769.0M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 13, 2024 | Time not confirmed | -0.54 | 0.00 | +100.0% |
| Mar 28, 2024 | Time not confirmed | -0.51 | 0.00 | +100.0% |
| Nov 14, 2023 | After the close | -0.57 | -0.44 | +22.8% |
| Aug 14, 2023 | After the close | -0.60 | -0.59 | +1.7% |
| May 10, 2023 | After the close | -0.59 | -0.60 | -1.7% |
| Mar 30, 2023 | After the close | -0.59 | -0.59 | 0.0% |
| Nov 14, 2022 | After the close | -0.57 | -0.55 | +3.5% |
| Aug 15, 2022 | After the close | -0.55 | -0.57 | -3.6% |
| May 16, 2022 | After the close | -0.49 | -0.60 | -22.4% |
| Mar 30, 2022 | After the close | -0.43 | -0.46 | -7.0% |
| Nov 15, 2021 | After the close | -0.49 | -1.30 | -165.3% |
| Sep 13, 2021 | After the close | -2.23 | -2.86 | -28.3% |
| Jun 2, 2021 | Time not confirmed | — |
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV…
| -0.51 |
| — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -2.11 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -1.76 | — |